 |
Company
An innovative life sciences company founded in 1993, INCELL is
developing an oral vaccine business utilizing its proprietary
platform technology for stimulating mucosal immunity. The company's
in-depth understanding of and experience with nanotechnology, bio
technology and the mucosal immune system have enabled the
development of its oral vaccine technology. We believe that our oral
vaccine technology, which delivers the immunogenic vaccine material
to the mouth and small intestine, thereby creating both mucosal and
systemic immunity, offers competitive advantages over other
vaccines. These advantages include efficacy gained from creating
mucosal immunities, cost, storage, and stability.
In addition to its developing vaccine business, INCELL develops,
markets and sells additional products and services:
Clinical Products
INCELL has new clinical products in the pipeline, primarily in the
areas of bioterrorism and defense; cell and passive immunotherapy;
antibodies, nutritional therapy and supplement products;
bioengineering with cell, gene and tissue-based therapeutics;
infectious disease; and pre-clinical testing. Diagnostic devices
(e.g., for viruses), vaccine therapies (i.e., an oral smallpox
vaccine), immunotherapy test kits, gene therapies against cancer and
several other products are in the pipeline. These include convergent
technologies for cybersecurity and patient monitoring with novel
engineering, nanotechnology and information technology tools.
Services
INCELL provides contract services to other companies. INCELL has
very broad-ranging scientific and management expertise that
includes: infectious disease, oncology, cell biology, toxicology,
microbiology, neurobiology, gene therapy, immunology, virology,
diabetes, tissue procurement, transplantation, pharmacology, AIDS
research, tissue modeling, wound healing, and cell baking.
Capabilities range from fundamental molecular or microbial analyses
to cell and animal studies to participation in clinical trials. The
majority of service work is client-customized, and INCELL
understands deliverables. Product design and management solutions,
information technologies capabilities, partnerships in statistical
analyses, database use and design, specialty products, expert
Consultant Scientists, client-customized contract research and
testing protocols, manufacturing capabilities, and contract
organizations, pharmaceutical, and biotechnology companies achieve
their R&D and product development goals.
Cell culture and research products
INCELL manufactures products for cell culture and research
applications. These include specialty reagents for stem cells, media
and supplements for culture and cryopreservation of human and animal
cells, monoclonal and polyclonal antibodies, nucleic acids,
proteins, viruses, viral reagents, nutritional supplements, and
other research reagents. INCELL has a bank of about 80,000 vials of
cryopreserved human cells from normal and diseased tissues for R&D
use. INCELL has the only continuous human stem cell lines derived
from the small intestine, colon, and blood stem cells. Some of these
are already licensed. Others are being patented as tools for
pre-clinical testing and possibly for transplantation.
|
